Abstract 474P
Background
Good overall and disease-free survival for small primary lung cancers may be achieved with sublobar resections. These cancers presented as undiagnosed solitary lung nodule and may be difficult to localise intra-operatively due to their size or their ground glass nature, necessitating a greater anatomical resection. Our institution had adopted the use of image guided coil localisation since 2017 to aid the excision of such nodules. The localisation was performed on the same day just prior to the lung resection surgery. We aimed to share our experience with this technique.
Methods
We reviewed the outcomes of all patients who underwent surgical excision for undiagnosed solitary lung nodule between 2018 and 2021 and compared the efficacy with patients who had coil localisation and those who did not.
Results
182 consecutive patients were reviewed in our study. 36 patients (19.8%) underwent coil localisation whilst 146 patients (80.2%) did not. There was no significant difference in the pre-operative lung function between the 2 groups of patients. 88.5% of nodules were malignant and there was no significant difference in incidence between both groups (coil 91.7% vs no coil 87.7%, p = 0.368). Lung resection was performed via uniportal video assisted thoracoscopic (UVATS) in all coiling cases whilst 9 non-coiling cases (6.2%) had open thoracotomy. Patients who had coiling were more likely to underwent wedge resection than an anatomical resection (OR 2.14, 95% CI 1.62-2.82, p < 0.001).The conversion rate was lower in patients who had underwent coil localisation (OR 0.72, 95% CI 0.27-1.98) but this was not statistically significant (p = 0.367). All patients who underwent coil localisation reported clear margins on final histology. Patient who underwent coil localisation had a shorter length of stay (mean 3.44 +/- 2.92 days) than those who did not (mean 4.07 +/- 3.21 days) (p = 0.290). There was no significant difference in complications between both group of patients.
Conclusions
Both diagnostic and cure can be achieved via UVATS wedge resection with the aid of coil localisation. Our study demonstrated it as a safe and effective method of managing suspicious small primary lung cancers presenting as a small solitary lung nodule.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract